FranTech Signs Agreement with NanoSignal

VENTURA, California. – NanoSignal Corp, an OTC Pink Sheet fully reporting company, symbol NNOS.OBPK, announced today that it has entered into an international licensing and franchising agreement with FranTech International Licensing, Inc. of Ventura, California.

Under the agreement FranTech will promote licenses and franchises in 220 countries. The licensees and franchises will have the right to market NanoSignal Corporation products including their proprietary SLICES™ technology.

"This represents the next step in the global development of the company," said NanoSignal President, Kelly Slade. “FranTech is the leader in international licensing and franchising opportunities worldwide.

“Over the next few months, NanoSignal will be establishing relationships with several other medical technology companies in joint marketing programs through FranTech licensing.
This will further enhance NanoSignal's position in the global market and will provide new revenue streams for the company”, reported Dr. Rupert Perrin, NanoSignal Chairman of the Board.

The company explained that FranTech's mission is to foster the development of the global economy by providing a global perspective to developers, marketers, manufacturers and innovators on newly emerging and preemptive technologies. They offer world-class solutions for the licensing and transfer of USA innovations to emerging economies.

Philip Nadeau, CEO of FranTech, said, "We see a tremendous market worldwide for NanoSignal’s products including its proprietary Slices™ technology and already have interest from several countries. We plan on developing brand name recognition and positioning of NanoSignal with many governmental agencies where we already have relationships in place."

About NanoSignal Corporation

NanoSignal is involved in the development and interface of state-of-the-art MRI data processing tools that provide significant processing and patient advantages compared to the other imaging software of its genre. NanoSignal is dedicated to promoting state-of-the data processing technologies to people from all ends of the globe.

The focus of NanoSignal is to develop technology, such as SLICES™, generating high quality images with low resolution raw data matrices, which allows for reduced patient scan times and more accurate diagnosis based upon the results. NanoSignal is uniquely positioned to address the MRI data processing needs of developing nations and industrial nations around the world.

About FranTech International Licensing, Inc.

FranTech consists of core partners surrounded by interlocking networks of consultants and affiliates in key trading countries and disciplines. They have over thirty-five years of experience with their proven partners. In addition, FranTech has proven track records in assembling, negotiating and consummating trade, licensing, technological and financial agreements; they pool strengths drawn from experience in international trade policy, law, marketing, investment banking and technology research. This broad expertise, coupled with access to key governmental and business decision makers, provides services uniquely valuable to NanoSignal in the restructuring global economy. NanoSignal is pleased to commence a strong working relationship with FranTech.

FranTech’s mission is to foster the development of the global economy by providing a Global Perspective to developers, marketers, manufactures, and innovators of newly emerging and preemptive technologies. They offer world-class solutions for the licensing and transfer of USA innovations to emerging economies in 220 countries worldwide for over thirty-five years.

Licenses are currently available in select countries.
For information on this exclusive technology contact FranTech:
(805) 653-5264, President@FranTechUSA.com


Safe Harbor Statement: Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will" or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission.